- Home
- DARE vs NRXS Comparison
DARE vs NRXS Comparison
Compare DARE & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DARE
- NRXS
- Stock Information
- Founded
- DARE 2015
- NRXS 2011
- Country
- DARE United States
- NRXS United States
- Employees
- DARE N/A
- NRXS N/A
- Industry
- DARE Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- DARE Health Care
- NRXS
- Exchange
- DARE Nasdaq
- NRXS Nasdaq
- Market Cap
- DARE 28.0M
- NRXS 25.0M
- IPO Year
- DARE N/A
- NRXS 2023
- Fundamental
- Price
- DARE $2.09
- NRXS $2.43
- Analyst Decision
- DARE Strong Buy
- NRXS Strong Buy
- Analyst Count
- DARE 2
- NRXS 1
- Target Price
- DARE $10.00
- NRXS $7.00
- AVG Volume (30 Days)
- DARE 182.2K
- NRXS 52.6K
- Earning Date
- DARE 08-14-2025
- NRXS 08-12-2025
- Dividend Yield
- DARE N/A
- NRXS N/A
- EPS Growth
- DARE N/A
- NRXS N/A
- EPS
- DARE N/A
- NRXS N/A
- Revenue
- DARE N/A
- NRXS $3,217,531.00
- Revenue This Year
- DARE $74,787.57
- NRXS $62.14
- Revenue Next Year
- DARE $141.76
- NRXS $131.87
- P/E Ratio
- DARE N/A
- NRXS N/A
- Revenue Growth
- DARE N/A
- NRXS 41.93
- 52 Week Low
- DARE $1.83
- NRXS $1.33
- 52 Week High
- DARE $9.19
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- DARE 44.08
- NRXS 46.25
- Support Level
- DARE $2.00
- NRXS $2.42
- Resistance Level
- DARE $2.19
- NRXS $2.68
- Average True Range (ATR)
- DARE 0.09
- NRXS 0.12
- MACD
- DARE 0.03
- NRXS 0.00
- Stochastic Oscillator
- DARE 34.78
- NRXS 40.42
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).